Kwas ryzedronowy: interakcje

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Pamidronate disodium is contraindicated in patients with hypersensitivity to pamidronate disodium, other bisphosphonates, or mannitol. (etykieta leku Kwas pamidronowy, Przeciwwskazania)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant administration of Risedronate sodium delayed-release and H 2 blockers or PPIs is not recommended. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Closely monitor for signs of renal toxicity when XELODA is used concomitantly with nephrotoxic drugs (e.g. platinum salts, irinotecan, methotrexate, intravenous bisphosphonates). (etykieta leku Kapecytabina, Interakcje z innymi lekami)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Suplementy i leki zobojętniające kwas żołądkowy zawierające magnez zmniejszają wchłanianie tych leków; dawki należy rozdzielić odstępem co najmniej dwóch godzin. (NIH Office of Dietary Supplements, Magnesium)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Oxybutynin chloride extended-release tablets should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis. (etykieta leku Oksybutynina, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (etykieta leku Sunitynib, Ostrzeżenia i środki ostrożności)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Calcium Supplements/Antacids When Risedronate sodium delayed-release was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [ see Clinical Pharmacology (12.3) ] . (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed. (etykieta leku Eksemestan, Ostrzeżenia i środki ostrożności)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Upper Gastrointestinal Adverse Reactions Risedronate sodium delayed-release, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Upper Gastrointestinal Adverse Reactions Risedronate sodium delayed-release, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Upper Gastrointestinal Adverse Reactions Risedronate sodium delayed-release, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. (etykieta leku Kwas ryzedronowy, Ostrzeżenia i środki ostrożności)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Hormone Therapy Concomitant use of Risedronate sodium delayed-release with estrogens and estrogen agonist/antagonists has not been studied. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)

Aspirin/Nonsteroidal Anti-Inflammatory Drugs In the Phase 3 study comparing Risedronate sodium delayed-release 35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. (etykieta leku Kwas ryzedronowy, Interakcje z innymi lekami)